echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Pioneer Pharmaceuticals and Fosun Pharma announce that the new drug "Prokalamide" is effective for severe COVID-19

    Pioneer Pharmaceuticals and Fosun Pharma announce that the new drug "Prokalamide" is effective for severe COVID-19

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Development Pharmaceutical Co.


    Prokalamide is a class 1.


    During the development process, there were many surprises.


    The discovery of the role of Prokalamide in the new crown involves a process of inductive reasoning and deductive reasoning


    In February 2020, Kaifeng Pharmaceutical and Soochow University collected and analyzed the clinical data of 1,339 patients with new crowns, and carried out a series of cell in vitro tests to analyze the underlying mechanism


    At the same time, there are many similar discoveries abroad


    As a result, Pioneer Pharmaceuticals got in touch with Applied Biology in the United States, and cooperated in Brazil to launch a clinical study of procluamide for the treatment of COVID-19 initiated by the researcher


    Inspired by the results of clinical trials for patients with mild and moderate new coronary disease, and with the strong support of the Brazilian health department, the clinical trial of procrulamide in the treatment of patients with severe new coronary disease has also obtained accelerated approval by the Brazilian Independent Review Board (IRB).


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.